Benitec Biopharma Limited
BNTC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow BNTC
Benitec Biopharma Limited (BNTC) Piotroski F-score
Benitec Biopharma Limited's Piotroski F-score for fiscal 2023 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2022.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2023 | 3 | 0.00 |
| FY2022 | 3 | 0.00 |
| FY2021 | 3 | (1.00) |
| FY2020 | 4 | (3.00) |
| FY2019 | 7 | 5.00 |
| FY2018 | 2 | (3.00) |
| FY2017 | 5 | — |
How fiscal 2023’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (374.86%) | (133.14%) | Fail | 0 |
| Positive operating cash flow | (18.01m) | (15.90m) | Fail | 0 |
| Rising return on assets | (374.86%) | (133.14%) | Fail | 0 |
| Cash flow above net income | 1.55m | 2.31m | Pass | 1 |
| Falling long-term leverage | 0.05 | 0.04 | Fail | 0 |
| Rising current ratio | 0.94 | 1.90 | Fail | 0 |
| No new shares issued | 1,386,000 | 480,700 | Fail | 0 |
| Rising gross margin | 100.00% | 87.67% | Pass | 1 |
| Rising asset turnover | 0.01 | 0.01 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | 5 |
| AGEN Agenus Inc. compare | 4 |
| BNTC Benitec Biopharma Limited | 3 |
| ARCT Arcturus Therapeutics Holdings Inc. compare | 2 |
| OCGN Ocugen, Inc. compare | 2 |
| SRZN Surrozen, Inc. compare | — |
| CTNM Contineum Therapeutics, Inc. compare | — |
| NAUT Nautilus Biotechnology, Inc. compare | — |
| ARTV Artiva Biotherapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover